Clinical Trial Update: A Study of MabThera/Rituxan (Rituximab) in Patients With Non-Bulky Follicular Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Rituximab (MabThera/Rituxan) in patients with non-bulky follicular non-Hodgkin's lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• MabThera/Rituxan (Rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED